We read with great interest the Article by Giacomo Montagna and colleagues,1 which addresses a pivotal question in contemporary breast cancer care—if axillary lymph node dissection (ALND) can be safely omitted in patients with residual micrometastases (ypN1mi) after neoadjuvant chemotherapy. Their multinational cohort provides much-needed outcome data to inform surgical de-escalation strategies. However, the significantly higher axillary recurrence rate observed…
[Correspondence] ALND after neoadjuvant chemotherapy: a call for caution
The Lancet Oncology | | Fady Sourial, Sushil Beriwal, Colin E Champ
Topics: breast-cancer, blood-cancer, chemotherapy